Difference between revisions of "Kaposi sarcoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|Years of enrollment" to "|Dates of enrollment") |
Warner-admin (talk | contribs) m (Text replacement - "7 PubMed" to "7/ PubMed") |
||
| Line 25: | Line 25: | ||
===References=== | ===References=== | ||
| − | #'''AMC 013:''' Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://doi.org/10.1200/JCO.2005.11.043 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15598977 PubMed] | + | #'''AMC 013:''' Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://doi.org/10.1200/JCO.2005.11.043 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15598977/ PubMed] |
[[Category:Kaposi sarcoma regimens]] | [[Category:Kaposi sarcoma regimens]] | ||
Revision as of 14:06, 4 May 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.
All lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed